Article citationsMore>>
Woessmann, W., Zimmermann, M., Lenhard, M., Burkhardt, B., Rossig, C., Kremens, B., Lang, P., Attarbaschi, A., Mann, G., Oschlies, I., Klapper, W. and Reiter, A. (2011) Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents after Berlin-Frankfurt-Muenster (BFM)-Type First-Line Therapy: A BFM-Group Study. Journal of Clinical Oncology, 29, 3065-3071.
https://doi.org/10.1200/JCO.2011.34.8417
has been cited by the following article:
-
TITLE:
Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma
AUTHORS:
Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya, Olga V. Aleinikova
KEYWORDS:
Anaplastic Large Cell Lymphoma, Relapse, Brentuximab Vedotin, Donor Lymphocyte Infusion, Minimal Residual Disease
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.8,
July
28,
2017
ABSTRACT: Minimal
residual disease (MRD) appears to have a strong negative predictive value for
disease recurrence in children with anaplastic large cell lymphoma (ALCL).
Brentuximab vedotin (BV) can be a therapeutic option for MRD-positive
patients to achieve molecular remission and to decrease risk of subsequent
relapse. We here report a 4-year-old child with ALCL progression during relapse
treatment who received BV as a bridging therapy before haploidentical
hematopoietic stem-cell transplantation, and as a maintenance therapy
post-transplant alone or combined with simultaneous low dose donor-lymphocyte
infusions. MRD monitoring showed a complete molecular response and reflected
both BV efficiency and graft-versus-lymphoma effect.
Related Articles:
-
Ratha Mlis, Matthias Schell, Perrine Marec Bérard, Nathalie Bleyzac, Didier Frappaz
-
Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya, Olga V. Aleinikova
-
Mohamed Saleh Metwally, Mahmoud Tawfik Mohamed, Ayman Shehata
-
Mónica Belinda Romero-Guadarrama, Leslie Elizmara Aguilar-Ayala, German Ott, Jorge Pérez-Espinosa
-
A. Prica, A. Pratzer, M. Cheung, K. Thompson, E. Piliotis, N. L. Berinstein, K. Imrie, R. Pradhan, A. Vyas, Z. Ghorab, D. Good, L. Zhang, R. Buckstein